Literature DB >> 33758684

Effort, avolition and motivational experience in schizophrenia: Analysis of behavioral and neuroimaging data with relationships to daily motivational experience.

Adam J Culbreth1, Erin K Moran2, Sri Kandala2, Andrew Westbrook3,4, Deanna M Barch1,2,5.   

Abstract

Recent research suggests that schizophrenia is associated with reduced effort allocation. We examined willingness to expend effort, neural correlates of effort allocation, and the relationship of effort to daily motivational experience in schizophrenia. We recruited 28 individuals with schizophrenia and 30 controls to perform an effort task during fMRI. Individuals with schizophrenia also completed an ecological momentary assessment (EMA) protocol. Individuals with schizophrenia with high negative symptoms were less willing to expend effort for rewards. Daily EMA assessments of motivation were positively associated with effort allocation at a trend-level. Individuals with schizophrenia and controls displayed similar increases in BOLD activation in frontal, cingulate, parietal, and insular regions during effort-based decision-making. However, negative symptoms were associated with reduced BOLD activation in bilateral ventral striatum. These results replicate previous reports of reduced effort allocation in schizophrenia patients with severe negative symptoms, and provide evidence for the role of ventral striatum in effort impairments.

Entities:  

Year:  2020        PMID: 33758684      PMCID: PMC7983405          DOI: 10.1177/2167702620901558

Source DB:  PubMed          Journal:  Clin Psychol Sci        ISSN: 2167-7034


  6 in total

1.  Deconstructing emotion regulation in schizophrenia: the nature and consequences of abnormalities at the identification stage.

Authors:  Ian M Raugh; Gregory P Strauss
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-10-30       Impact factor: 5.760

2.  Anhedonia in Schizophrenia.

Authors:  Erin K Moran; Adam J Culbreth; Deanna M Barch
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  Digital phenotyping adherence, feasibility, and tolerability in outpatients with schizophrenia.

Authors:  Ian M Raugh; Sydney H James; Cristina M Gonzalez; Hannah C Chapman; Alex S Cohen; Brian Kirkpatrick; Gregory P Strauss
Journal:  J Psychiatr Res       Date:  2021-04-30       Impact factor: 5.250

4.  Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.

Authors:  Michael Davidson; Jay Saoud; Corinne Staner; Nadine Noel; Sandra Werner; Elisabeth Luthringer; David Walling; Mark Weiser; Philip D Harvey; Gregory P Strauss; Remy Luthringer
Journal:  Schizophr Bull       Date:  2022-05-07       Impact factor: 7.348

5.  Tracing Links Between Early Auditory Information Processing and Negative Symptoms in Schizophrenia: An ERP Study.

Authors:  Giulia M Giordano; Francesco Brando; Andrea Perrottelli; Giorgio Di Lorenzo; Alberto Siracusano; Luigi Giuliani; Pasquale Pezzella; Mario Altamura; Antonello Bellomo; Giammarco Cascino; Antonio Del Casale; Palmiero Monteleone; Maurizio Pompili; Silvana Galderisi; Mario Maj
Journal:  Front Psychiatry       Date:  2021-12-20       Impact factor: 4.157

6.  Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia.

Authors:  Giulia M Giordano; Andrea Perrottelli; Armida Mucci; Giorgio Di Lorenzo; Mario Altamura; Antonello Bellomo; Roberto Brugnoli; Giulio Corrivetti; Paolo Girardi; Palmiero Monteleone; Cinzia Niolu; Silvana Galderisi; Mario Maj
Journal:  Brain Sci       Date:  2021-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.